NCT02903095
Completed
Phase 1
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD-1439 in Healthy Subjects
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Theravance Biopharma
- Enrollment
- 66
- Locations
- 1
- Primary Endpoint
- Safety of TD-1439 by assessing the number and severity of adverse events, including changes in vital signs, physical examination, laboratory safety tests, and ECGs
Overview
Brief Summary
Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy subjects
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 19 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Body Mass Index (BMI) 18 to 32 kg/m2 inclusive
- •Women of child bearing potential must have a negative pregnancy test and either abstain from sex or use highly effective methods of birth control
- •Women of non-childbearing potential are at least 2 years postmenopausal or are surgically sterile
- •Males must abstain from sex or use highly effective methods of birth control
- •Negative for HIV, and Hepatitis A, B, and C
Exclusion Criteria
- •Female subjects who are pregnant, lactating, breastfeeding or planning to become pregnant during the study.
- •Subjects with a history of angioedema.
- •Subject has evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease.
- •Subject has acute illness (gastrointestinal, infection \[e.g., influenza\] or known inflammatory process)
- •Subject bradycardia
- •Subject has hypertension
- •Subjects has orthostatic hypotension
- •Subjects has orthostatic tachycardia
- •Subject has a known personal or family history of congenital long QT syndrome or known family history of sudden death.
- •Subject has donated blood or blood components or has had blood loss exceeding 400 mL within the 90 days prior to Screening.
Arms & Interventions
TD-1439
Experimental
Capsule formulation
Intervention: TD-1439 (Drug)
Placebo
Placebo Comparator
Capsule formulation
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Safety of TD-1439 by assessing the number and severity of adverse events, including changes in vital signs, physical examination, laboratory safety tests, and ECGs
Time Frame: From Day 1 through end of study (Day 10)
Secondary Outcomes
- PK of TD-1439 in plasma after multiple doses - time to peak plasma concentration (Tmax)(Day 1 through Day 10)
- PK of TD-1439 in plasma after multiple doses - area under the plasma concentration vs. time curve from time zero to 24 hours postdose (AUC0-24)(Day 1 through Day 10)
- PK of TD-1439 in plasma after multiple doses - time to last measurable concentration (Tlast)(Day 1 through Day 10)
- PK of TD-1439 in plasma after multiple doses - area under the plasma concentration vs. time curve from time zero to the last quantifiable concentration (AUC0-t)(Day 1 through Day 10)
- PK of TD-1439 in urine after multiple doses - Fe (fraction of oral dose excreted in urine)(Day 1 through Day 10)
- PK of TD-1439 in plasma after multiple doses - CL/F (oral plasma clearance)(Day 1 through Day 10)
- Pharmacodynamic assessments for urine atrial natriuretic peptide (ANP) concentrations(The day before dosing (Day -1) to 3 days after last dose (Day 4))
- Pharmacodynamic assessments for plasma cyclic guanosine monophosphate (cGMP) concentrations(The day before dosing (Day -1) to 3 days after last dose (Day 4))
- Pharmacokinetics (PK) of TD-1439 in plasma after multiple doses - peak plasma concentration (Cmax)(Day 1 through Day 10)
- PK of TD-1439 in urine after multiple doses - Ae (amount excreted in urine)(Day 1 through Day 10)
- Pharmacodynamic assessments for plasma atrial natriuretic peptide (ANP) concentrations(The day before dosing (Day -1) to 3 days after last dose (Day 4))
- PK of TD-1439 in plasma after multiple doses - Vz/F (apparent volume of distribution during the terminal phase)(Day 1 through Day 10)
- PK of TD-1439 in plasma after multiple doses - t1/2 (half-life)(Day 1 through Day 10)
- PK of TD-1439 in urine after multiple doses - Clr (renal clearance)(Day 1 through Day 10)
- Pharmacodynamic assessments for urine cyclic guanosine monophosphate (cGMP) concentrations(The day before dosing (Day -1) to 3 days after last dose (Day 4))
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Single Ascending Dose Study of TD-0714 in Healthy SubjectsHealthyNCT02639078Theravance Biopharma56
Completed
Phase 1
Single Ascending Dose Study of CM326 in Healthy VolunteersAsthmaNCT04842201Keymed Biosciences Co.Ltd44
Completed
Phase 1
Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly SubjectsHealthy Adults, Elderly SubjectsNCT02954263Theravance Biopharma40
Completed
Phase 1
Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly SubjectsHealthy Adults, Elderly SubjectsNCT02709928Theravance Biopharma50
Completed
Phase 1
Single Ascending Dose Study of WAL0921 in Healthy SubjectsHealthyNCT05891366Walden Biosciences40